Ge Longhui, December 30 | Xinhua Healthcare (600587.SH) announced that it intends to acquire Shenzhen Meijian Electronic Technology Development Co., Ltd., Shenzhen Meijian Electronic Technology Development Co., Ltd., natural person Ding Yeqing, natural person Wang Zhanbao, Shanghai Shengyu Heike Venture Capital Center (limited partnership), natural person Lian Qingming, natural person Zhuang Jinhui, natural person Dong Yan, natural person Liu Weibing, and Shenzhen Xipeng private equity investment fund partnership (limited partnership) jointly owned by Wuhan Zhongzhi Biotechnology Co., Ltd. (limited partnership) (“Zhongqi Biotech” for short, stock code: 836834) 36.1913% equity.
Zhongzhi Biotech is mainly engaged in R&D, production and sales of RNA molecular in vitro diagnostic kits and supporting instruments and consumables. The main products are respiratory infection pathogen detection series products, reproductive tract infection pathogen detection series products, and intestinal infection pathogen detection series products. Through the acquisition of Zhongzhi Biotech, Xinhua Medical will further enrich its in vitro diagnostic business product line, achieve a segmented layout for pathogenic microorganism testing, enhance the technical capabilities of Xinhua Medical's product research and development, and further enhance the overall competitiveness of Xinhua Medical. At the same time, once Zhongji Biotech becomes a holding subsidiary of the company, it will also further enrich capital operation channels, play business synergy effects in customer development, resource maintenance, etc., and create new business growth points.